BRISBANE, Calif., Oct. 28, 2015 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq:CDNA), a molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high-value, diagnostic surveillance solutions for transplant recipients, today announced that it will release financial results for the third quarter 2015 after the close of trading on Wednesday, November 11, 2015. Peter Maag, Chief Executive Officer and President, and Ken Ludlum, Chief Financial Officer, will host a corresponding conference call beginning at 1:30pm PT/4:30pm ET.
Individuals interested in listening to the conference call may do so by dialing (855) 420-0616 for domestic callers or +1 (678) 304-6848 for international callers. Please reference Conference ID 43132259. To listen to a live webcast, please visit the investor relations section of CareDx’s website at: www.caredx.com.
A replay of the call will be available beginning November 11, 2015 at 4:30pm PT/7:30pm ET through midnight on November 12, 2015. To access the replay, dial (855) 859-2056 or (404) 537-3406 and reference Conference ID: 43132259. The webcast will also be available on CareDx’s website for one year following the completion of the call.
About CareDx
CareDx, Inc., based in Brisbane, California, is a molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high-value, non-invasive diagnostic surveillance solutions for transplant recipients. The Company has commercialized AlloMap®, a gene expression test that aids clinicians in identifying heart transplant recipients with stable graft function who have a low probability of moderate/severe acute cellular rejection. CareDx is also pursuing the development of additional products for post-transplant monitoring of other solid organs that use a variety of technologies, including next generation sequencing to detect donor-derived cell-free DNA to monitor the health of organs after transplantation. The Company is currently investigating a research use only donor-derived cell-free DNA-based test for heart transplant recipients. For more information, please visit: www.CareDx.com.
CONTACT: Media Contact Molly Martell Senior Director, Marketing T: +1 415-287-2397 E: mmartell@caredx.com Investor Contact Westwicke Partners, LLC Leigh J. Salvo, Principal T: +1 415-513-1281 E: leigh.salvo@westwicke.com
Help employers find you! Check out all the jobs and post your resume.
